Active Biotech AB Interim report January - June 2016
(Thomson Reuters ONE) -
Laquinimod
* The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing
according to plan
* The study results from both the pivotal clinical Phase 3 CONCERTO trial in
relapsing remitting multiple sclerosis (RRMS) and the Phase 2 study
ARPEGGIO, evaluating laquinimod for the treatment of primary progressive
multiple sclerosis (PPMS), are expected in the first half of 2017
* Positive results concerning laquinimod were presented at the 68th AAN Annual
Meeting (American Academy of Neurology), held in Vancouver, Canada, on April
15-21, 2016
Tasquinimod
* The complete study results of the Phase 3 10TASQ10 study have been published
in the Journal of Clinical Oncology
* Out-licensing activities are continuing
ANYARA, Paquinimod (57-57) and SILC (ISI)
* Out-licensing activities are continuing
Financial summary
SEK M Q2 Q1-Q2 Full Year
2016 2015 2016 2015 2015
-------------------------------------------------------------------------------
Net sales 3.9 3.2 7.9 6.1 16.3
Operating loss -14.5 -70.1 -30.6 -127.5 -177.9
Loss for the period -15.5 -71.4 -32.3 -129.3 -193.5
Loss per share, before and after dilution -0.17 -0.79 -0.36 -1.44 -2.15
(SEK)
Cash and cash equivalents (at the end of 57.4 186.6 103.6
the period)
* Refocusing of the company is completed, operating costs reduced by 71% (SEK
95.2 M) compared with 2015
* The number of employees will be reduced from 56 (June 2015) to 17 by the end
of the third quarter of 2016
* Operations are progressing according to plan pending the Phase 3 results for
laquinimod in the first half of 2017
For further information, please contact:
Tomas Leanderson, President and CEO Active Biotech AB
Tel: +46 46 19 20 95 (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Hans Kolam, CFO Tel: +46 46 19 20 00
Tel: +46 46 19 20 44 Fax: +46 46 19 11 05
The report is also available at www.activebiotech.com.
Active Biotech AB (publ) Interim Report January - June 2016:
http://hugin.info/1002/R/2034058/757619.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via GlobeNewswire
[HUG#2034058]
Unternehmensinformation / Kurzprofil:
Datum: 11.08.2016 - 08:30 Uhr
Sprache: Deutsch
News-ID 488520
Anzahl Zeichen: 3361
contact information:
Town:
LUND
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 200 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Active Biotech AB Interim report January - June 2016"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
